Boehringer Ingelheim and Zealand Pharma's survodutide - a dual glucagon/GLP-1 receptor agonist - produced up to 16.6% mean weight loss at 76 weeks in the phase 3 SYNCHRONIZE-1 obesity trial, with a striking 34% reduction in visceral fat and a 63% reduction in liver fat versus 25% on placebo. Roughly 85% of treated patients achieved at least 5% weight loss. Published in Diabetes, Obesity and Metabolism (Wharton et al., 2025), the data differentiate survodutide on body-composition and MASLD (fatty liver) benefits rather than raw weight-loss magnitude, where it trails the triple-agonist retatrutide.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.